Diabetes research and clinical practice
-
Diabetes Res. Clin. Pract. · Feb 2011
Case ReportsSevere leucopenia associated with Sitagliptin use.
We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment.